Laser vision correction specialist LCA-Vision (LCAV) is poised for an epic rebound. After suffering through a multi-year recession, it has quietly re-emerged as more disciplined and efficient organization, with the most attractive long-term growth prospects in company history. Significant pent-up demand and a game-changing demographic inflection point remain under-appreciated by the market. Given the substantial operating leverage in LCA-Vision's fixed cost business model, disciplined investors could reap a 200% TSR in the next 36 months. Downside risk is mitigated by adroit financial management and a robust balance sheet with $1.80 per share net cash.
Reasons to Consider LCAV
The trifecta of headwinds that punished shareholders over these past five years have quietly transitioned to tail winds.